Masimo Co. (NASDAQ:MASI) Shares Bought by Fmr LLC

Fmr LLC lifted its holdings in shares of Masimo Co. (NASDAQ:MASI) by 41.2% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 6,756,618 shares of the medical equipment provider’s stock after buying an additional 1,970,883 shares during the quarter. Fmr LLC owned approximately 0.13% of Masimo worth $900,860,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Farallon Capital Management LLC lifted its position in Masimo by 13.6% during the 1st quarter. Farallon Capital Management LLC now owns 1,489,563 shares of the medical equipment provider’s stock worth $218,742,000 after acquiring an additional 177,914 shares during the period. Westfield Capital Management Co. LP lifted its holdings in shares of Masimo by 23.2% during the third quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider’s stock worth $185,869,000 after purchasing an additional 262,370 shares during the period. Thrivent Financial for Lutherans grew its position in Masimo by 42.1% in the 2nd quarter. Thrivent Financial for Lutherans now owns 1,217,357 shares of the medical equipment provider’s stock valued at $153,314,000 after buying an additional 360,497 shares during the last quarter. Massachusetts Financial Services Co. MA increased its stake in Masimo by 9.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 792,166 shares of the medical equipment provider’s stock valued at $105,619,000 after buying an additional 70,440 shares during the period. Finally, Point72 Asset Management L.P. raised its position in Masimo by 107.8% during the 2nd quarter. Point72 Asset Management L.P. now owns 677,677 shares of the medical equipment provider’s stock worth $85,347,000 after buying an additional 351,523 shares during the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently issued reports on MASI. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research note on Wednesday, November 6th. Raymond James upgraded Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 target price on the stock in a research report on Wednesday, November 6th. Wells Fargo & Company boosted their target price on shares of Masimo from $160.00 to $171.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. Stifel Nicolaus restated a “buy” rating and issued a $190.00 price target (up previously from $170.00) on shares of Masimo in a report on Friday, November 22nd. Finally, Piper Sandler lifted their price objective on Masimo from $165.00 to $180.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $167.00.

Masimo Trading Down 0.8 %

NASDAQ:MASI opened at $170.89 on Thursday. The firm has a market capitalization of $9.15 billion, a PE ratio of 117.86 and a beta of 0.97. Masimo Co. has a 12 month low of $91.60 and a 12 month high of $178.27. The business’s 50-day moving average is $147.03 and its two-hundred day moving average is $129.03. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11.

Masimo (NASDAQ:MASI) last posted its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business had revenue of $504.60 million for the quarter, compared to analysts’ expectations of $502.87 million. During the same period in the previous year, the company posted $0.63 earnings per share. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. Research analysts predict that Masimo Co. will post 4.04 earnings per share for the current fiscal year.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.